Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,capitalExpenditures,netBorrowings,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,marketState,currency,exchange,shortName,market,priceHint,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,exchangeDataDelayedBy,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jun 14, 2021) 4","Short Ratio (Jun 14, 2021) 4","Short % of Float (Jun 14, 2021) 4","Short % of Shares Outstanding (Jun 14, 2021) 4","Shares Short (prior month May 13, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,EVLO,87839000.0,53373900,21508000,,-28074000,,-28196000,5963000,0,-27471000,-27471000,,-800000,,,,122000,0,27471000,0,-603000,,-28196000,-28196000,408501000.0,65203000.0,87839000.0,686000.0,153042000.0,53000.0,263000.0,-320715000.0,7763000.0,1313000.0,124591000.0,18719000.0,17548000.0,134181000.0,7500000.0,29258000.0,380000.0,6438000.0,-314000.0,82328000.0,-1391000.0,82328000.0,55734000.0,-26280000.0,536000.0,-7500000.0,3833000.0,-314000.0,,,115462000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NMS,"Evelo Biosciences, Inc.",us_market,2,NasdaqGS,"Evelo Biosciences, Inc.",USD,175396,113966,7.62,1.9947644,3.82 - 19.928,-8.488,-0.42593336,3.82,19.928,1619679602,1635337800,1635769800,-2.233,-2.2,-2.21,0,-5.1764703,1.646,10.384444,1.0555553,0.10164774,12.068406,-0.6284065,-0.052070383,623390720,-5.2,6.950182,15,America/New_York,EDT,-14400000,False,False,0.61565256,11.31 - 11.5644,11.37,11.5,11.63,12,9,finmb_331329033,11.44,1630510349,0.069999695,11.31,11.5644,11.31,8853,1.31,,,19.93,3.82,10.38,12.07,175.4k,113.97k,53.37M,,27.05M,0.48%,89.81%,2.54M,20,10.90%,4.76%,3.01M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-50.86%,-155.40%,,,,,-94.03M,-98.82M,-2.23,,124.59M,2.33,41.38M,47.10,7.17,1.65,-79.83M,-52.59M,Value,02139,Healthcare,90,8,5,"Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 577 0300,MA,7,1609372800,1625011200,10,United States,http://www.evelobio.com,86400,10,620 Memorial Drive,Biotechnology,5th Floor
t-1,EVLO,30485000.0,53373900,22113000,,-28862000,,-29050000,6085000,0,-28198000,-28198000,,-1100000,,,,188000,0,28198000,0,-664000,,-29050000,-29050000,322957000.0,60154000.0,30485000.0,463000.0,90639000.0,47000.0,263000.0,-292519000.0,284000.0,1424000.0,68857000.0,19833000.0,18235000.0,70980000.0,,30048000.0,1442000.0,-1268000.0,-409000.0,6702000.0,7899000.0,6702000.0,-12660000.0,-18953000.0,533000.0,-7500000.0,2933000.0,-409000.0,,,51147000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NMS,"Evelo Biosciences, Inc.",us_market,2,NasdaqGS,"Evelo Biosciences, Inc.",USD,175396,113966,7.62,1.9947644,3.82 - 19.928,-8.488,-0.42593336,3.82,19.928,1619679602,1635337800,1635769800,-2.233,-2.2,-2.21,0,-5.1764703,1.646,10.384444,1.0555553,0.10164774,12.068406,-0.6284065,-0.052070383,623390720,-5.2,6.950182,15,America/New_York,EDT,-14400000,False,False,0.61565256,11.31 - 11.5644,11.37,11.5,11.63,12,9,finmb_331329033,11.44,1630510349,0.069999695,11.31,11.5644,11.31,8853,1.31,,,19.93,3.82,10.38,12.07,175.4k,113.97k,53.37M,,27.05M,0.48%,89.81%,2.54M,20,10.90%,4.76%,3.01M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-50.86%,-155.40%,,,,,-94.03M,-98.82M,-2.23,,124.59M,2.33,41.38M,47.10,7.17,1.65,-79.83M,-52.59M,Value,02139,Healthcare,90,8,5,"Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 577 0300,MA,7,1609372800,1625011200,10,United States,http://www.evelobio.com,86400,10,620 Memorial Drive,Biotechnology,5th Floor
t-2,EVLO,50430000.0,53373900,14910000,,-20856000,,-20923000,5272000,0,-20182000,-20182000,,-600000,,,,67000,0,20182000,0,-674000,,-20923000,-20923000,313853000.0,54407000.0,50430000.0,389000.0,104837000.0,46000.0,,-263469000.0,432000.0,1500000.0,81580000.0,13548000.0,18778000.0,84559000.0,,29924000.0,2729000.0,-707000.0,-261000.0,9887000.0,362000.0,6702000.0,-8593000.0,-18219000.0,462000.0,-7500000.0,2587000.0,-261000.0,10000000.0,-113000.0,71011000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NMS,"Evelo Biosciences, Inc.",us_market,2,NasdaqGS,"Evelo Biosciences, Inc.",USD,175396,113966,7.62,1.9947644,3.82 - 19.928,-8.488,-0.42593336,3.82,19.928,1619679602,1635337800,1635769800,-2.233,-2.2,-2.21,0,-5.1764703,1.646,10.384444,1.0555553,0.10164774,12.068406,-0.6284065,-0.052070383,623390720,-5.2,6.950182,15,America/New_York,EDT,-14400000,False,False,0.61565256,11.31 - 11.5644,11.37,11.5,11.63,12,9,finmb_331329033,11.44,1630510349,0.069999695,11.31,11.5644,11.31,8853,1.31,,,19.93,3.82,10.38,12.07,175.4k,113.97k,53.37M,,27.05M,0.48%,89.81%,2.54M,20,10.90%,4.76%,3.01M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-50.86%,-155.40%,,,,,-94.03M,-98.82M,-2.23,,124.59M,2.33,41.38M,47.10,7.17,1.65,-79.83M,-52.59M,Value,02139,Healthcare,90,8,5,"Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 577 0300,MA,7,1609372800,1625011200,10,United States,http://www.evelobio.com,86400,10,620 Memorial Drive,Biotechnology,5th Floor
t-3,EVLO,69206000.0,53373900,15174000,,-20563000,,-20652000,5071000,0,-20245000,-20245000,,-400000,,,,89000,0,20245000,0,-318000,,-20652000,-20652000,311706000.0,44699000.0,69206000.0,395000.0,113905000.0,46000.0,,-242546000.0,303000.0,1570000.0,90173000.0,13608000.0,19618000.0,92717000.0,,19806000.0,3439000.0,2247000.0,-216000.0,48650000.0,-1174000.0,48650000.0,32058000.0,-16376000.0,540000.0,-7500000.0,2663000.0,-216000.0,10000000.0,-113000.0,79109000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,REGULAR,USD,NMS,"Evelo Biosciences, Inc.",us_market,2,NasdaqGS,"Evelo Biosciences, Inc.",USD,175396,113966,7.62,1.9947644,3.82 - 19.928,-8.488,-0.42593336,3.82,19.928,1619679602,1635337800,1635769800,-2.233,-2.2,-2.21,0,-5.1764703,1.646,10.384444,1.0555553,0.10164774,12.068406,-0.6284065,-0.052070383,623390720,-5.2,6.950182,15,America/New_York,EDT,-14400000,False,False,0.61565256,11.31 - 11.5644,11.37,11.5,11.63,12,9,finmb_331329033,11.44,1630510349,0.069999695,11.31,11.5644,11.31,8853,1.31,,,19.93,3.82,10.38,12.07,175.4k,113.97k,53.37M,,27.05M,0.48%,89.81%,2.54M,20,10.90%,4.76%,3.01M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-50.86%,-155.40%,,,,,-94.03M,-98.82M,-2.23,,124.59M,2.33,41.38M,47.10,7.17,1.65,-79.83M,-52.59M,Value,02139,Healthcare,90,8,5,"Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.",Cambridge,617 577 0300,MA,7,1609372800,1625011200,10,United States,http://www.evelobio.com,86400,10,620 Memorial Drive,Biotechnology,5th Floor
